World pharmaceutical and biopharmaceutical market, 2010 2015 (pipeline analysis of the top 50 companies)

1,357 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,357
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
34
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

World pharmaceutical and biopharmaceutical market, 2010 2015 (pipeline analysis of the top 50 companies)

  1. 1. Get more info on this report!World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (PipelineAnalysis of the Top 50 Companies)July 1, 2010 What Will The Pharmaceutical Market Look Like in the Next Five Years?In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 topcompanies in pharmaceuticals -- the companies that produce the lions share of industryrevenues. While the report looks at the entire pipeline to 2015, a key focus of the reportis the increasing role of biopharmaceutical products. The growing interest inbiotechnology development has transitioned the pharmaceutical industry tobiopharmaceuticals in less than a decade. Companies such as Pfizer, Merck andNovartis have been unable to ignore the benefits of investing in biotechnology and havefocused on a pipeline in this direction through strategic acquisitions and partnershipswith biotech companies and/or through their own in-house research efforts.This Kalorama Information market research report, The World Pharmaceutical andBiopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50Companies) captures these trends, extracting sales for all pharmaceutical andbiopharmaceutical products (excluding prophylactic vaccines) and providing estimatesand forecasts of the world biopharma market.Among the top companies in biopharmaceuticals are, not surprisingly, the same namesthat have dominated pharmaceuticals for years - Pfizer, Merck and Novartis. Thesecompanies have been unable to ignore the benefits of investing in biotechnology andhave focused on a pipeline in this direction through strategic acquisitions andpartnerships with biotech companies and/or through their own in-house research efforts.Specialist companies such as Amgen and Genzyme, now competing with a growingnumber of companies. The result of all interest in biological solutions to major diseases?In creased activity in the research and development departments of majorpharmaceutical companies in recent years, activity that we believe will have near-termmarket impact. Key Issues and Trends in the Industry
  2. 2. Issues and Trends discussed in this report include: Biotechnology Drug Development Orphan Drugs Fast Track Drug Status Other Accelerated Methods for Drug Approval Pharmaceutical Regulatory Exclusivity Biosimilar Development Aging Populations Mergers, Acquisitions, and Collaborations Contributors to R&D Success R&D Spending Trends The Role of Contract Research Organizations Sustainability in a Changing Pharmaceutical IndustryAlso, despite an in-depth interview process and complete review of company financials,some variation in company rankings is possible. This is more likely with privately heldcompanies or companies where prescription pharmaceutical and biopharmaceuticalsales are not discussed.In this comprehensive look a the pipeline of major companies, Kalorama Informationpresents an accurate picture of the marketplace today, including Market Estimates by Major Drug Category, including: o Cardiovascular/Blood o Neurotherapeutics o Infection o Oncology o Respiratory/Inflammatory o Gastrointestinal o Other Discussion of Marketplace Trends Pipeline Analysis of Major Pharmacos Detailed Company Profiles Comparison of Market at Current Growth Versus Impact of Late-Stage Products Biopharmaceutical Market Breakdown Best-Selling Biopharmaceutical Products Regulatory Activity and Market ImpactKalorama Informations market research into this topic is based on review ofgovernment filings and company literature, but also interviews with executives andexperts, and the perspective of an analyst who has authored scores of reports in thisindustry. Late Stage Product Development of the Top 50 Companies
  3. 3. 50 top companies make up over 90% of the world biopharmaceutical market; The topthree companies have nearly a quarter of global sales in 2009.Kalorama looks at each key players late-stage pipeline in detail. The top 50 companiesdiscussed in this report include: Abbott Actelion Alcon, Inc. Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Boehringer Ingelheim Bristol-Myers Squibb Celgene Corp. Cephalon Chugai Pharmaceutical CSL Daiichi Sankyo Dainippon Eisai Eli Lilly & Co. Endo Forest Genzyme Gilead Sciences GlaxoSmithKline Hospira Johnson & Johnson Lundbeck Menarini Merck Merck KGaA Mitsubishi Tanabe Pharma Mylan Novartis Novo Nordisk Nycomed Ono Pharmaceutical Co. Otsuka Pharmaceutical Pfizer Procter & Gamble
  4. 4. Purdue Pharma Roche Sanofi-Aventis Servier Shionogi Shire Takeda TEVA UCB WatsonTable of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Potential Market Opportunity Issues and Trends Affecting Market Leading CompaniesCHAPTER TWO: INTRODUCTION Global Pharmaceutical Market Pharmaceutical Research & Development Overview o Clinical Trial CostsCHAPTER THREE: ISSUES AND TRENDS Biotechnology Drug Development Orphan Drugs Fast Track Drug Status Other Accelerated Methods for Drug Approval Pharmaceutical Regulatory Exclusivity Pediatric Extensions Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation Aging Population Mergers, Acquisitions, and Collaborations Contributors To R&D Success R&D Spending The Role of Contract Research Organizations Sustainability in a changing Pharmaceutical Industry
  5. 5. CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS Introduction Pfizer, Inc./Wyeth (merged in 2009) o Overview o Financial Performance and Investments o Late Stage Pipeline Merck & Co., Inc. o Overview o Financial Performance and Investments o Late Stage Pipeline Novartis AG o Overview o Financial Performance and Investments o Late Stage Pipeline Roche Ltd. o Overview o Financial Performance and Investments o Late Stage Pipeline Sanofi-Aventis o Overview o Financial Performance and Investments o Late Stage Pipeline AstraZeneca plc o Overview o Financial Performance and Investments o Late Stage Pipeline GlaxoSmithKline plc o Overview o Financial Performance and Investments o Late Stage Pipeline Johnson & Johnson o Overview o Financial Performance and Investments o Late Stage Pipeline Eli Lilly & Company o Overview o Financial Performance and Investments o Late Stage Pipeline Bristol-Myers Squibb Company o Overview o Financial Performance and Investments o Late Stage Pipeline Abbott Laboratories o Overview o Financial Performance and Investments
  6. 6. o Late Stage Pipeline Takeda Pharmaceutical Co., Ltd. o Overview o Financial Performance and Investments o Late Stage Pipeline Bayer AG o Overview o Financial Performance and Investments o Late Stage Pipeline Amgen, Inc. o Overview o Financial Performance and Investments o Late Stage Pipeline Boehringer Ingelheim GmbH o Overview o Financial Performance and Investments o Late Stage Pipeline TEVA Pharmaceutical Industries, Ltd. o Overview o Financial Performance and Investments o Late Stage Pipeline Astellas o Overview o Financial Performance and Investments o Late Stage Pipeline Daiichi Sankyo o Overview o Financial Performance and Investments o Late Stage Pipeline Novo Nordisk o Overview o Financial Performance and Investments o Late Stage Pipeline Eisai o Overview o Financial Performance and Investments o Late Stage PipelineCHAPTER FIVE: COMPANIES OF INTEREST Introduction Otsuka o Late Stage Pipeline Merck KGaA o Late Stage Pipeline
  7. 7. Gilead Sciences Late Stage PipelineMylan o PipelineBaxter International o Late Stage PipelineChugai Pharmaceutical Company, Ltd. o Late Stage PipelineMitsubishi Tanabe o Late Stage PipelineServier, Les Laboratories o PipelineUCB SA o Late Stage PipelineAllergan o Late Stage PipelineForest Laboratories o Late Stage PipelineNycomed International o Late Stage PipelineGenzyme Corporation o Late Stage PipelineBiogen Idec o Late Stage PipelineHospira o Late Stage PipelineWatson o PipelineCSL Limited o Late Stage PipelineAlcon o Late Stage PipelineShire o Late Stage PipelineCelgene Corporation o Late Stage PipelineLundbeck o Late Stage PipelineShionogi & Co., Ltd. o Late Stage PipelineMenarini Group o Late Stage PipelineDainippon Sumitomo Pharma, Co., Ltd. o Late Stage Pipeline
  8. 8. Cephalon o Late Stage Pipeline Actelion o Late Stage Pipeline Procter & Gamble Endo Pharmaceuticals o Late Stage Pipeline Ono Pharmaceutical Co. o Late Stage Pipeline Purdue Pharma o Late Stage PipelineCHAPTER SIX: MARKET FORECAST Overview Company Analysis Pipeline Snapshot: Top 50 Companies Current Market Value Market ForecastCHAPTER SEVEN: BIOPHARMACEUTICAL MARKET Biopharmaceutical Companies Biopharmaceutical Market Forecast APPENDIX: LIST OF COMPANIESTABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions) Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluatedCHAPTER TWO: INTRODUCTION Table 2-1: Phases of Clinical Drug Development Table 2-2: Components of a Clinical TrialCHAPTER THREE: ISSUES AND TRENDS Table 3-1: International Population Trend Age 65+ Figure 3-1: International Population Trend Age 65+ Table 3-2: United States Population Trend Age 65+ Figure 3-2: International Population Trend Age 65+
  9. 9. Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics Figure 3-3: Drug Development Cost Progression Table 3-5: Total Industry R&D Spending 2004-2009 Figure 3-4: Total Industry R&D Spending 2004-2009CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions) Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-3: Pfizer’s Late Stage Product Pipeline Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-5: Merck & Co.’s Late Stage Product Pipeline Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-7: Novartis’ Late Stage Product Pipeline Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-9: Roche’s Late Stage Product Pipeline Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007- 2009 (Millions) Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007- 2009 (Millions) Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007- 2009 (Millions) Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007- 2009 (Millions) Table 4-13: AstraZeneca’s Late Stage Product Pipeline Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
  10. 10. Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending2007-2009 (Millions)Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending2007-2009 (Millions)Table 4-15: GlaxoSmithKline’s Late Stage Product PipelineFigure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic AreaTable 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending2007-2009 (Millions)Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending2007-2009 (Millions)Table 4-17: Johnson & Johnson’s Late Stage Product PipelineFigure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by TherapeuticAreaTable 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009(Millions)Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009Table 4-19: Eli Lilly’s Late Stage Product PipelineFigure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic AreaTable 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending2007-2009 (Millions)Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending2007-2009 (Millions)Table 4-21: Bristol-Myers Squibb’s Late Stage Product PipelineFigure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic AreaTable 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009(Millions)Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009(Millions)Table 4-23: Abbott’s Late Stage Product PipelineFigure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic AreaTable 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009(Millions)Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009(Millions)Table 4-25: Takeda Pharmaceutical’s Late Stage Product PipelineFigure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline byTherapeutic AreaTable 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009(Millions)Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009(Millions)Table 4-27: Bayer’s Late Stage Product PipelineFigure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic AreaTable 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009(Millions) Figure 4-27: Amgen’s Total Company Revenue and R&D Spending2007-2009 (Millions)
  11. 11. Table 4-29: Amgen’s Late Stage Product Pipeline Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Table 4-33: TEVA’s Late Stage Product Pipeline Figure 4-32: TEVA’s Late Stage Product Pipeline by Therapeutic Area Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions) Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions) Table 4-35: Astellas’ Late Stage Product Pipeline Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007- 2009 (millions) Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions) Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007- 2009 (millions) Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007- 2009 (millions) Table 4-39: Novo Nordisk’s Late Stage Product Pipeline Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009 (Thousands) Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009 Table 4-41: Eisai’s Late Stage Product Pipeline Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic AreaCHAPTER FIVE: COMPANIES OF INTEREST Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area Table 5-3: Merck KGaA’s Late Stage Product Pipeline
  12. 12. Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic AreaTable 5-4: Gilead Sciences’ Late Stage Product PipelineFigure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic AreaTable 5-5: Baxter International’s Late Stage Product PipelineFigure 5-4: Baxter International’s Late Stage Product Pipeline by TherapeuticAreaTable 5-6: Chugai Pharmaceutical’s Late Stage Product PipelineFigure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic AreaTable 5-7: Mitsubishi Tanabe’s Late Stage Product PipelineFigure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic AreaTable 5-8: UCB Pharma’s Late Stage Product PipelineFigure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic AreaTable 5-9: Allergan’s Late Stage Product PipelineFigure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic AreaTable 5-10: Forest Laboratories’ Late Stage Product PipelineFigure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic AreaTable 5-11: Nycomed’s Late Stage Product PipelineFigure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic AreaTable 5-12: Genzyme’s Late Stage Product PipelineFigure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic AreaTable 5-13: Biogen Idec’s Late Stage Product PipelineFigure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic AreaTable 5-14: Hospira’s Late Stage Product PipelineFigure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic AreaTable 5-15: CSL’s Late Stage Product PipelineFigure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic AreaTable 5-16: Alcon’s Late Stage Product PipelineFigure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic AreaTable 5-17: Shire’s Late Stage Product PipelineFigure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic AreaTable 5-18: Celgene’s Late Stage Product PipelineFigure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic AreaTable 5-19: Lundbeck’s Late Stage Product PipelineFigure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic AreaTable 5-20: Shionogi’s Late Stage Product PipelineFigure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic AreaTable 5-21: Menarini’s Late Stage Product PipelineFigure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic AreaTable 5-22: Dainippon Sumitomo’s Late Stage Product PipelineFigure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by TherapeuticAreaTable 5-23: Cephalon’s Late Stage Product PipelineFigure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic AreaTable 5-24: Actelion’s Late Stage Product PipelineFigure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic AreaTable 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline
  13. 13. Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area Table 5-27: Purdue Pharma’s Late Stage Product Pipeline Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic AreaCHAPTER SIX: MARKET FORECAST Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions) Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues) Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues) Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues) Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues) Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005- 2010 ($ in billions) Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005- 2010 Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions) Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage DevelopmentCHAPTER SEVEN: BIOPHARMACEUTICAL MARKET Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2691449
  14. 14. US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004

×